https://doi.org/10.55788/7e412546
Prof. Jaclyn Smith (University of Manchester, UK) presented the findings of the SOOTHE study [1]. The rationale behind the study is that refractory chronic cough typically lasts >8 weeks and does not respond to treatment of possible associated disease or is simply not associated with a disease. There are no approved treatment options. Hypersensitation of cough signalling pathways, including the P2X3 receptor, is thought to play a key role in refractory chronic cough, and P2X3 antagonists have shown some promise in clinical trials [2].
SOOTHE is a randomised, double-blind, placebo-controlled, parallel-arm, dose-finding, phase 2b trial (NCT04678206) of the investigational drug BLU-5937, which is a P2X3 antagonist with high selectivity. After a 3-week run-in period, 249 enrolled participants with more than 25 awake coughs/hour were randomised to either placebo twice daily (n=63) or to BLU-5937 12.5 mg (n=62), 50 mg (n=62), or 200 mg twice daily (n=62). In addition, 61 participants whose baseline cough frequency was between 10ā25 coughs/hour were randomised to receive either placebo (n=30) or BLU-5937 200 mg twice daily (n=31). Treatment was provided for 28 days, and follow-up continued until day 43, 2 weeks after the final dose. Demographics and baseline characteristics were well-balanced across all treatment arms. The primary endpoint of the trial was change in objective cough frequency, as measured over 24 hours and calculated in the log-transformed geometric means ratio.
The results showed that the higher doses of BLU-5937 of 50 mg and 200 mg met the primary endpoint. The placebo-adjusted change in 24-hour cough frequency in the 12.5 mg arm dropped by 18.3% at day 15, and by 21.1% at day 28; although those reductions were not significant. However, for the 50 mg and 200 mg arms, coughing was reduced by 32ā34% at day 15, which was sustained at 34% at day 28, with all measurements being significant (2-sided P<0.005). The absolute change in cough frequency was 53% for both 50 mg and 200 mg doses from baseline compared with a 28% absolute reduction in the placebo arm. The dose-finding part of the trial concluded that there was a dose-response between 12.5 and 50 mg, with no additional clinical benefit observed beyond 50 mg.
With regard to safety, no serious adverse events were reported, and similar mild adverse events were reported for placebo as for BLU-5937. Notably, mild taste disturbances were reported in the BLU-5937 arms, although none resulted in partial or total loss of taste. Prof. Smith concluded that both the important reductions in cough frequency as well as the observed, favourable safety profile support the continued clinical development of this P2X3 antagonist.
- Smith JA, et al. Safety and efficacy of BLU-5937 in the treatment of refractory chronic cough from the phase 2b SOOTHE trial. Session C93, ATS International Conference 2022, San Francisco, CA, USA, 13ā18 May.
- Abdulqawi R, et al. Lancet. 2015;385(9974):1198ā205.
Copyright Ā©2022 Medicom Medical Publishers
Posted on
Previous Article
« Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis Next Article
Home-based rehabilitation improves COPD: a randomised study »
« Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis Next Article
Home-based rehabilitation improves COPD: a randomised study »
Table of Contents: ATS 2022
Featured articles
Letter from the Editor
COVID-19
Nebulised aviptadil āfutileā in I-SPY COVID-19 trial
Lung transplantation after COVID-19-associated ARDS
Mesenchymal stem cells offer no benefit in COVID-19
Alpha-1 antitrypsin for ARDS secondary to severe COVID-19
Frailty prevalent 5 months following hospitalisation for COVID-19
Paediatric long COVID lacks definitions
Asthma Clinical Trial Updates
MANDALA and DENALI pattern success for albuterol-budesonide in asthma
ACOUSTICS data sounds good for adolescent asthma exacerbations
Type 2 asthma in children managed by dupilumab, despite atopic comorbidities
NAVIGATOR steers asthma patients to tezepelumab
High-intensity interval training slashes daily corticosteroids in asthma
Chronic Obstructive Pulmonary Disease
Threeās a crowd for triple therapy in COPD
Higher 1-year COPD mortality after hospitalisation for White patients
Reducing dyspnoea in chronic lung disease through weight loss
CT-evident mucus plugs in COPD associated with death
Home-based rehabilitation improves COPD: a randomised study
Highlighted Advances
Novel P2X3 antagonist can SOOTHE chronic cough
Colistimethate sodium PROMISing for non-cystic fibrosis bronchiectasis
Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?
PAGANINI phase 2b data promising for eliapixant
POISE-3: Tranexamic acid for non-cardiac surgery
Obstructive sleep apnoea in most children with pulmonary hypertension
No screening evidence for COPD
Novel PDE4B inhibitor offers breakthrough for IPF
Hydrocortisone does not help preterm infants
CPAP temporarily supports pulmonary oxygenation in morbidly obese patients
ISAACC trial: CPAP controls blood pressure in ACS patients with severe OSA
Related Articles
October 29, 2020
CPAP withdrawal has negative consequences for sleep apnoea patients
Ā© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com